<DOC>
	<DOCNO>NCT01929655</DOCNO>
	<brief_summary>To evaluate efficacy safety best standard care plus BAY88-8223 Japanese patient CRPC bone metastases multiple administration</brief_summary>
	<brief_title>Japanese BAY88-8223 Monotherapy Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Have receive docetaxel eligible first course docetaxel , i.e . patient fit enough willing . Histologically cytologically confirm adenocarcinoma prostate Multiple bone metastases Either regular ( occasional ) analgesic medication use cancerrelated bone pain treatment external beam radiotherapy ( EBRT ) bone pain . Best standard care ( BSoC ) regard routine standard care . Exclusion Criteria : Treatment cytotoxic chemotherapy within previous 4 week , plan treatment period History visceral metastasis , presence visceral metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase II</keyword>
	<keyword>symptomatic castration-resistant prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>